Sonnet Biotherapeutics Inc., of Princeton, said it completed the discovery phase for its immunotherapy platform and commenced CMC development. Its platform leverages a scaffold based on the firm's albumin binding single chain antibody fragment for delivery of recombinant human-cytokines and other validated targets.